Q-omics provides the consensus-scored SNX19 profile across patient tissues and cancer cell-line models. SNX19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNX19 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SNX19 RNA expression shows 20,223 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where SNX19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX19 survival associations across molecular data types. SNX19 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX19 RNA expression–survival associations across cancer types. High SNX19 expression shows unfavorable associations in BLCA, ACC, UVM and HNSC, but favorable associations in UCS and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNX19 RNA expression.
This table summarizes SNX19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SNX19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX19 shows lower tumor expression in KIRC, THCA, COAD and KICH and higher tumor expression in HNSC and CHOL. The KIRC box plot shows higher SNX19 RNA expression in normal versus tumor tissue (log2 FC = −0.755, t-test p < 0.001).
This table shows molecular features associated with SNX19 in patient tissues and cancer cell lines. In patient samples, SNX19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
